Atossa Therapeutics Inc
NASDAQ:ATOS

  • LAST PRICE
    1.1950
  • TODAY'S CHANGE (%)
    0.0050 (0.4202%)
  • Bid / Lots
    1.1900/ 20
  • Ask / Lots
    1.2000/ 60
  • Open / Previous Close
    1.2000 / 1.1900
  • Day Range
    1.1700
    1.2200
  • 52 Week Range
    0.7000
    2.3100
  • Volume
    703,763

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Nov 20, 2024

  • Nov 13, 2024

  • Nov 12, 2024

      Show headlines and story abstract

    • 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: ATOS
      September 30, 2024 December 31, 2023 -------------------- ------------------- Assets --------------------------- Current assets Cash and cash equivalents $ 74,766 $ 88,460 Restricted cash 110 110 Prepaid materials 1,285 1,487 Prepaid expenses and other current assets 950 2,162 ---------------- --------------- Total current assets 77,111 92,219 ---------------- --------------- Investment in equity securities -- 1,710 Other assets 2,366 2,323 ---------------- --------------- Total assets $ 79,477 $ 96,252 ================ =============== Liabilities and stockholders' equity --------------------------- Current liabilities Accounts payable $ 1,561 $ 806 Accrued expenses 1,694 973 Payroll liabilities 1,061 1,654 Other current liabilities 1,480 1,803 ---------------- --------------- Total current liabilities 5,796 5,236 ---------------- --------------- Total liabilities 5,796 5,236 ---------------- --------------- Commitments and contingencies Stockholders' equity Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock - $0.18 par value; 350,000,000 and 175,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 125,801,254 and 125,304,064 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 22,882 22,792 Additional paid-in capital 257,719 255,987 Treasury stock, at cost; 1,320,046 shares of common stock at September 30, 2024 and December 31, 2023 (1,475) (1,475) Accumulated deficit (205,445) (186,288) ---------------- --------------- Total stockholders' equity 73,681 91,016 ---------------- --------------- Total liabilities and stockholders' equity $ 79,477 $ 96,252 ================ =============== ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except share and per share data) (Unaudited) For the Three Months Ended For the Nine Months Ended September 30, September 30, --------------------------- --------------------------- 2024 2023 2024 2023 ------------ ------------ ------------ ------------ Operating expenses Research and development $ 3,412 $ 4,467 $ 10,714 $ 11,680 General and administrative 2,973 3,001 9,756 10,678 ----------- ----------- ----------- ----------- Total operating expenses 6,385 7,468 20,470 22,358 ----------- ----------- ----------- ----------- Operating loss (6,385) (7,468) (20,470) (22,358) Impairment charge on investment in equity securities (1,710) -- (1,710) (2,990) Interest income 1,001 1,274 3,213 3,107 Other expense, net (136) (35) (190) (99) ----------- ----------- ----------- ----------- Loss before income taxes (7,230) (6,229) (19,157) (22,340) Income tax benefit -- -- -- -- ----------- ----------- ----------- ----------- Net loss (7,230) (6,229) (19,157) (22,340) =========== =========== =========== =========== Net loss per share of common stock - basic and diluted $ (0.06) $ (0.05) $ (0.15) $ (0.18) =========== =========== =========== =========== Weighted average shares outstanding used to compute net loss per share - basic and diluted 125,772,664 125,793,112 125,608,794 126,343,629 =========== =========== =========== ===========

    • 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: ATOS
      September 30, 2024 December 31, 2023 -------------------- ------------------- Assets --------------------------- Current assets Cash and cash equivalents $ 74,766 $ 88,460 Restricted cash 110 110 Prepaid materials 1,285 1,487 Prepaid expenses and other current assets 950 2,162 ---------------- --------------- Total current assets 77,111 92,219 ---------------- --------------- Investment in equity securities -- 1,710 Other assets 2,366 2,323 ---------------- --------------- Total assets $ 79,477 $ 96,252 ================ =============== Liabilities and stockholders' equity --------------------------- Current liabilities Accounts payable $ 1,561 $ 806 Accrued expenses 1,694 973 Payroll liabilities 1,061 1,654 Other current liabilities 1,480 1,803 ---------------- --------------- Total current liabilities 5,796 5,236 ---------------- --------------- Total liabilities 5,796 5,236 ---------------- --------------- Commitments and contingencies Stockholders' equity Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of September 30, 2024 and December 31, 2023 -- -- Common stock - $0.18 par value; 350,000,000 and 175,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 125,801,254 and 125,304,064 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 22,882 22,792 Additional paid-in capital 257,719 255,987 Treasury stock, at cost; 1,320,046 shares of common stock at September 30, 2024 and December 31, 2023 (1,475) (1,475) Accumulated deficit (205,445) (186,288) ---------------- --------------- Total stockholders' equity 73,681 91,016 ---------------- --------------- Total liabilities and stockholders' equity $ 79,477 $ 96,252 ================ =============== ATOSSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (amounts in thousands, except share and per share data) (Unaudited) For the Three Months Ended For the Nine Months Ended September 30, September 30, --------------------------- --------------------------- 2024 2023 2024 2023 ------------ ------------ ------------ ------------ Operating expenses Research and development $ 3,412 $ 4,467 $ 10,714 $ 11,680 General and administrative 2,973 3,001 9,756 10,678 ----------- ----------- ----------- ----------- Total operating expenses 6,385 7,468 20,470 22,358 ----------- ----------- ----------- ----------- Operating loss (6,385) (7,468) (20,470) (22,358) Impairment charge on investment in equity securities (1,710) -- (1,710) (2,990) Interest income 1,001 1,274 3,213 3,107 Other expense, net (136) (35) (190) (99) ----------- ----------- ----------- ----------- Loss before income taxes (7,230) (6,229) (19,157) (22,340) Income tax benefit -- -- -- -- ----------- ----------- ----------- ----------- Net loss (7,230) (6,229) (19,157) (22,340) =========== =========== =========== =========== Net loss per share of common stock - basic and diluted $ (0.06) $ (0.05) $ (0.15) $ (0.18) =========== =========== =========== =========== Weighted average shares outstanding used to compute net loss per share - basic and diluted 125,772,664 125,793,112 125,608,794 126,343,629 =========== =========== =========== ===========

Peers Headlines